Table 2.
Clinical characteristics of patients in the three study groups defined according to whether or not patients received oxaliplatin-based chemotherapy and experienced sinusoidal injury
| Characteristic | All (n= 29) | No-OX (n= 8) | OX + no-SI (n= 15) | OX + SI (n= 6) | P-valuea |
|---|---|---|---|---|---|
| Age, years, median (IQR) | 62 (56–71) | 73 (61–77) | 59 (55–66) | 57 (55–63) | 0.044 |
| Body mass index, kg/m2, median (IQR) | 27.2 (25.1–29.8) | 27.8 (24.2–37.4) | 27.8 (26.0–30.0) | 25.9 (23.7–27.3) | 0.270 |
| Synchronous CRLM, n | 16 | 2 | 9 | 5 | 0.082 |
| Number of tumours, median (IQR) | 2 (1–3) | 1 (1–3) | 2 (1–4) | 3 (1–6) | 0.209 |
| Maximal tumour diameter, mm, median (IQR) | 25 (19–50) | 23 (20–54) | 25 (20–49) | 20 (10–60) | 0.687 |
| Platelet count, ×109/l, median (IQR) | 236 (203–270) | 257 (224–308) | 237 (200–281) | 206 (190–212) | 0.064 |
| Number of OX cycles, median (IQR) | 5 (4–7) | – | 5 (4–7) | 6 (4–7) | 0.843 |
| Interval between OX treatment and surgery, weeks, median (IQR) | 6 (4–34) | – | 6 (4–29) | 18 (4–109) | 0.613 |
a
Kruskal–Wallis test was used to compare the distributions of continuous variables and the chi-squared test was used to compare nominal variables among the three groups.
No-OX, patients who did not receive oxaliplatin-based chemotherapy; OX + no-SI, patients who received oxaliplatin-based chemotherapy without sinusoidal injury; OX + SI, patients who received oxaliplatin-based chemotherapy with sinusoidal injury; IQR, interquartile range; CRLM, colorectal liver metastasis.